DBCO-Liposome (PEGylated) is a liposome conjugated with a dibenzocyclooctyne (DBCO) group.
It is used for targeted delivery, facilitating the attachment of various ligands, such as antibodies or peptides, to liposomes.
PEGylation increases liposome circulation time in the body, enhances biocompatibility, and reduces immunogenicity.
Cholesterol enhances the liposome's membrane fluidity and stability.
Confocal fluorescence microscopy images showing the influence of different MSNP coatings on the uptake of nanoparticles in A549 and HepG2 cells.
This study focuses on the conjugation of antibodies with nanoparticles to enhance targeting efficiency. The researchers functionalized the antibodies with dibenzylcyclooctyne (DBCO) while attaching azide (N3) groups to the nanoparticles (N₃-PEI-MSNPs). Subsequently, the antibody was covalently linked to the nanoparticles through copper-free click chemistry between the azide moiety and the DBCO-labeled antibody, resulting in αCD44 PEI-MSNPs. The targeting results demonstrated that αCD44 PEI-MSNPs can selectively target A549 cells with high CD44 expression. This research highlights the critical role of DBCO in the conjugation of antibodies and nanoparticles, showcasing significant potential for improving the targeting efficiency of nanoparticles.
Van Zundert, Indra, et al. "Versatile and Robust Method for Antibody Conjugation to Nanoparticles with High Targeting Efficiency." Pharmaceutics 13.12 (2021): 2153.
Distributed under Open Access license CC BY 4.0, without modification.
Click the button below to contact us or submit your feedback about this product.
Online Inquiry